November 2024's Top Insider-Owned Growth Companies

As global markets navigate the uncertainties surrounding the incoming Trump administration's policies, investors are closely watching sector performances, with financials and energy benefiting from deregulation hopes while healthcare faces challenges. Amidst this backdrop of fluctuating market sentiments and policy shifts, growth companies with high insider ownership can offer unique insights into potential long-term value creation.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Archean Chemical Industries (NSEI:ACI)	22.9%	43%
On Holding (NYSE:ONON)	31%	29.7%
Pharma Mar (BME:PHM)	11.8%	56.4%
Findi (ASX:FND)	34.8%	64.8%
Alkami Technology (NasdaqGS:ALKT)	11%	98.6%
Elliptic Laboratories (OB:ELABS)	26.8%	103.6%
Credo Technology Group Holding (NasdaqGS:CRDO)	13.8%	95%
Plenti Group (ASX:PLT)	12.8%	107.6%
EHang Holdings (NasdaqGM:EH)	32.8%	81.4%
Brightstar Resources (ASX:BTR)	16.2%	84.6%

Click here to see the full list of 1547 stocks from our Fast Growing Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

Oscotec (KOSDAQ:A039200)

Simply Wall St Growth Rating: ★★★★★★

Overview: Oscotec Inc. is a biotechnology company involved in drug development, functional materials, and dental bone graft materials, with a market cap of approximately ₩916.74 billion.

Operations: The company generates revenue from its Food Business Division (₩1.69 billion), Medical Business Sector (₩1.63 billion), New Drug Business Division (₩990.90 million), and Functional Materials Division (₩310.71 million).

Insider Ownership: 26.1%

Earnings Growth Forecast: 122% p.a.

Oscotec is forecast to achieve profitability within three years, with earnings expected to grow 122% annually. Despite having limited current revenue (₩5B), its projected revenue growth of 68.9% per year significantly outpaces the Korean market's average. The company's high future Return on Equity of 27.5% reflects strong potential performance. However, its share price has been highly volatile recently, and it trades at a substantial discount to estimated fair value, indicating potential undervaluation opportunities.

• Click here to discover the nuances of Oscotec with our detailed analytical future growth report.
• Our expertly prepared valuation report Oscotec implies its share price may be too high.

Norva24 Group (OM:NORVA)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Norva24 Group AB (Publ) offers underground infrastructure maintenance services in Northern Europe and has a market cap of SEK5.28 billion.

Operations: The company generates revenue from its underground infrastructure maintenance services in Northern Europe, with total revenue segments amounting to NOK2.45 billion.

Insider Ownership: 10.6%

Earnings Growth Forecast: 22.9% p.a.

Norva24 Group's recent earnings report shows a decline in net income despite revenue growth, with NOK 49 million for Q3 2024 compared to NOK 70.4 million a year ago. Analysts expect earnings to grow significantly at 22.9% annually, surpassing the Swedish market average of 15.2%. Insider transactions reveal more buying than selling recently, though not in substantial volumes. The stock trades at a significant discount to its estimated fair value and is expected to rise by analysts' consensus estimates.

• Delve into the full analysis future growth report here for a deeper understanding of Norva24 Group.
• Insights from our recent valuation report point to the potential undervaluation of Norva24 Group shares in the market.

RaySearch Laboratories (OM:RAY B)

Simply Wall St Growth Rating: ★★★★★☆

Overview: RaySearch Laboratories AB is a medical technology company that offers software solutions for cancer care across various regions, with a market cap of SEK6.41 billion.

Operations: The company generates revenue from its healthcare software segment, amounting to SEK1.13 billion.

Insider Ownership: 23.6%

Earnings Growth Forecast: 26.2% p.a.

RaySearch Laboratories has seen substantial insider buying over the past three months, indicating confidence in its growth trajectory. The company's earnings are projected to grow significantly at 26.2% annually, outpacing the Swedish market average. Recent orders from prominent institutions like Institut Curie and GenesisCare UK highlight strong demand for its RayStation system, contributing to revenue growth forecasts of 11.6% per year. The stock is trading well below estimated fair value, suggesting potential upside based on current analyst estimates.

• Dive into the specifics of RaySearch Laboratories here with our thorough growth forecast report.
• Our valuation report unveils the possibility RaySearch Laboratories' shares may be trading at a discount.

Where To Now?

• Delve into our full catalog of 1547 Fast Growing Companies With High Insider Ownership here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com